Advances in prostate cancer (PCa) research have led to the development of novel therapies for the metastatic castration-resistance (CRPC) form of the disease, such as two recent drugs abiraterone [1, 2] and enzalutamide [3, 4], which target the androgen receptor (AR) pathway. This evidence concerns the gene AR and prostate cancer.